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 27 
Abstract 28 
Envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is an 29 
important target for the development of an HIV vaccine.  Extensive glycosylation of Env 30 
is an important feature that both protects the virus from antibody responses and serves 31 
as a target for some highly potent broadly neutralizing antibodies.  Therefore, analysis 32 
of glycans on recombinant Env proteins is highly significant.  Here we present 33 
glycosylation profiles of recombinant gp120 proteins from four major clades of HIV-1 (A, 34 
B, C, and AE) produced either as research-grade material in 293 and CHO cells or as 35 
two independent lots of clinical material under GMP conditions.  Almost all potential N-36 
linked glycosylation sites were at least partially occupied in all proteins.  The occupancy 37 
rates were largely consistent among proteins produced under different conditions, 38 
although a few sites showed substantial variability even between two GMP lots.  Our 39 
data confirmed previous studies in the field showing high abundance of oligomannose 40 
on Env protein, with 40-50% of glycans having Man5-Man9 on all four proteins under all 41 
production conditions.  Overall the differences in occupancy and glycan forms among 42 
Env from different subtypes produced under different conditions were less dramatic than 43 
anticipated and antigenicity analysis with a panel of six monoclonal antibodies showed 44 
that all four gp120s maintained their antibody-binding profiles, including antibodies that 45 
recognize glycan forms.  Such findings have major implications to the final production of 46 
a clinical HIV vaccine including Env glycoprotein components. 47 
 48 
  49 
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Importance 50 
HIV-1 Env protein is a major target for the development of an HIV-1 vaccine.  Env is 51 
covered with a large number of sugar-based glycan forms – about 50% of the Env 52 
molecular weight is composed of glycans.  Glycan analysis of recombinant Env proteins 53 
is important to understand its roles in vial pathogenesis and immune responses.  The 54 
current report presents the first extensive comparison of glycosylation patterns of 55 
recombinant gp120 proteins from four major clades of HIV-1 produced in two different 56 
cell lines, grown at either laboratory condition or at 50L GMP scale across different lots. 57 
Information learned in this study is valuable for the further design and production of HIV-58 
1 Env proteins as the critical components of HIV-1 vaccine formulations.   59 
  60 
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Introduction 61 
The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) plays 62 
the key role in viral entry and serves as a major target for a preventive HIV-1 vaccine.  63 
Env is heavily glycosylated with N-glycans comprising about half of its molecular weight.  64 
In the course of HIV-1 evolution, either within an individual patient or on the population 65 
level, viral gene mutations may lead to the disappearance of certain glycosylation sites 66 
and to the appearance of new ones.  This shifting glycan shield protects the Env 67 
proteins from the engagement of antibodies elicited during the course of viral infection 68 
and contributing to the growth of escaping viral mutants in chronic infection (1).  69 
Nevertheless, some glycan features are highly conserved even across clades such that 70 
glycans contribute to several key antigenic domains recognized by broadly neutralizing 71 
antibodies.  For example, the highly conserved N332 glycan is important for the binding 72 
of monoclonal antibodies (mAbs) PGT128 and 10-1074, while N160 glycan is 73 
recognized by mAbs PG9 and PG16 (2, 3).  Another conserved feature of HIV glycan 74 
shield is high abundance of unusual oligomannose forms, which normally serve as 75 
intermediates in mammalian glycan synthesis (4–6). 76 
 77 
Glycosylation pattern can be expected to vary depending on multiple factors impacting 78 
glycoprotein synthesis, including the viral strain, the form in which Env is expressed 79 
(gp120, gp140, gp160), the cell type, the protein expression levels, and even the 80 
metabolic state of the cell (7).  In past studies, the exact proportion of oligomannose on 81 
Env varied from 17% to 98% with levels of 40-75% being common for both monomeric 82 
gp120 and native trimers (5, 8, 9).  However, analysis of two batches of membrane-83 
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anchored Env showed remarkable consistency of forms found at each glycosylation site 84 
(9, 10), indicating that glycosylation patterns are generally preserved when the same 85 
Env protein is produced under identical conditions and that the differences in 86 
oligomannose content reflect either virus- or host cell specific factors.   87 
 88 
In previous studies the viral clade-specific differences in the abundance of 89 
oligomannose have been attributed to the differences in the total number and regional 90 
density of the glycosylation sites, with higher glycan densities correlating with higher 91 
oligomannose content (4).  On the other hand, comparisons of glycosylation of the 92 
same Env proteins expressed in 293 and CHO cells revealed mostly similar 93 
oligomannose content, similar occupancy, and similar glycan profiles, but with some 94 
notable exceptions (11, 12).  It was observed that more complex glycans were present 95 
on CHO-derived clade C gp120 as compared to 293-derived protein, particularly at two 96 
sites (N386 and N392).   97 
 98 
The increasing understanding of the impact of glycans on HIV Env immunogenicity and 99 
the increased focus on recombinant Env proteins after the RV144 trial led to the 100 
growing appreciation of the importance of these features to the design of Env-based 101 
protein vaccines against HIV-1(13).  In particular, characterization of glycan profiles of 102 
recombinant Env proteins will be important to interpret the resulting antibody responses.   103 
 104 
Various approaches of producing and purifying recombinant Envs for laboratory 105 
research and for clinical studies can be employed, but there’s limited information based 106 
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on well-controlled studies for how different approaches may impact Env glycosylation.  107 
While transiently-transfected 293 cells are often used to produce research-grade 108 
proteins, the proteins for clinical use are usually produced in stably transfected CHO 109 
cells. Clinical material is usually produced in bioreactors that have larger volumes and 110 
reach higher cell density than those used in research-grade protein production. Diverse 111 
purification processes are used both in the lab and during clinical-grade protein 112 
purification, such as antibody-based affinity columns, size-exclusion chromatography, 113 
lectin-based columns, or the industry preferred ion-exchange columns.  Recently, a few 114 
recombinant GMP-grade Env-based vaccines have been characterized by analysis of 115 
glycans (14, 15) but the number of Env proteins included in those studies was limited 116 
and they did not provide direct comparison between different cell lines or between GMP 117 
and non-GMP for the production of the same Env proteins.       118 
 119 
Here we expanded the study to characterize glycosylation profiles of four recombinant 120 
gp120 proteins from four major clades of HIV-1 (subtypes A, B, C, and AE) produced 121 
under GMP condition for a Phase I human clinical trial (HVTN124).  We analyze two 122 
separate GMP lots of the same four gp120 proteins comparing them to the same four 123 
gp120 proteins produced under non-GMP condition in CHO and 293F cells.  Our results 124 
provide much needed information on the Env glycan patterns among different viral 125 
clades and between different preparations of the same protein.  Such information is not 126 
only valuable for the better understanding on the variation of Env glycan patterns but 127 
also critical for the establishment of quality control standards for the production of 128 
clinical grade Env-based HIV-1 vaccines.   129 
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Results 130 
HIV-1 gp120 Env proteins from four clades and produced under different 131 
conditions   132 
The four gp120 glycoproteins included in the current study were selected based on the 133 
immunogenicity analysis of a large panel of HIV-1 Env variants (16) and were included 134 
in a polyvalent DNA prime-protein boost HIV vaccine formulation currently going 135 
through a phase I clinical study at HIV Vaccine Trials Network (HVTN, protocol 124).  136 
They represent three primary isolates from clades A, B, and C, as well as a consensus 137 
variant from the AE clade.  Their amino acid sequences have a low homology to each 138 
other in the range of 75-80 % (Fig.1A).  They have 23-26 potential N-linked 139 
glycosylation sites (PNGSs), which are distributed throughout the sequence in a similar, 140 
but distinct manner (Fig.1B). 141 
 142 
Research-grade gp120 proteins were produced by transient transfection of 293F cells 143 
and from stably-transfected CHO cells in a laboratory setting and the proteins were 144 
purified using lectin-based columns.  For the GMP manufacturing process, stably 145 
transfected CHO cells expressing each of the proteins were grown in 50L bioreactors 146 
and the purification process involved ion-exchange columns.  Two separate GMP 147 
manufacturing runs have been done under identical conditions, which allowed us the 148 
opportunity to compare the consistency of glycosylation profiles from one GMP lot to 149 
another.   150 
 151 
Glycan analysis of research-grade proteins 152 
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Glycan heterogeneity for gp120 proteins produced as research-grade reagents in CHO 153 
and 293F cell lines were first analyzed.  Digestion with PNGase F was used to release 154 
glycans from the gp120 proteins and the released glycans were permethylated and 155 
analyzed by NSI-MSn to characterize glycan structural features.  Representative 156 
profiles for clade B gp120 are shown on Fig. 2A.  The types of glycan forms found on 157 
proteins produced in CHO and 293F cells were generally very similar and only a few 158 
types comprised more than 10% of the total glycans (Fig. 2B).  A large proportion of 159 
oligomannose forms (Man7-Man9) was detected in both preparations.  A diverse group 160 
of complex glycans were also present, as well as some hybrid forms.  The results for 161 
proteins from three other clades were similar (data not shown). 162 
 163 
To study occupancy rate at each PNGS, proteins were digested with several proteases 164 
to produce peptides for LC/MS analysis and then consecutively digested with EndoH 165 
and PNGase F to allow detection of occupancy by different types of glycans at each 166 
PNGS.  Digestion with EndoH cleaves N-linked glycans between the two N-167 
acetylglucosamine (GlcNAc) residues in the core region of the glycan chain on high-168 
mannose and hybrid, but not complex, glycans, leaving one GlcNAc still bound to the 169 
protein. Treatment with PNGase F removes all glycans that have not been impacted by 170 
EndoH treatment and leaves an aspartic acid residue at the site of N-linked 171 
glycosylation, which can be distinguished from the original asparagine by mass 172 
spectrometry of the peptides.  Therefore, consecutive digestion with EndoH and 173 
PNGaseF allowed us to distinguish between oligomannose and complex glycans at 174 
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each site.  The presence of the original asparagine in the peptide indicates that the 175 
PNG site has not been glycosylated.  176 
 177 
Analysis of PNGS occupancy of research grade 293F- and CHO-produced proteins 178 
showed that most of PNGSs were at least partially occupied in both cases (Fig. 3A). 179 
N141, N186 and N339 in clade B protein, N186 and N397 in clade C protein, and N465 180 
in clade AE protein were the only sites that showed less than 20% occupancy in our 181 
analysis. A large proportion of oliogomannose glycans was observed for all four gp120 182 
proteins, with higher proportions in glycans described as innate mannose patch.  183 
 184 
Glycosylation profiles of proteins produced in 293F and CHO cells were remarkably 185 
similar (Fig. 3B).  Most of the variation in occupancy was under 30 percentage points.  186 
Clade B proteins showed the largest variation with CHO-produced protein being more 187 
glycosylated than 293-produced protein. In some cases the changes were not in the 188 
total occupancy, but in the relative abundance of oligomannose and complex glycans. 189 
For example, N262 in clade B proteins was almost 100% occupied, but 293-produced 190 
protein carried an equal mixture of oligomannose and complex glycans, and CHO-191 
produced proteins had almost exclusively oligomannose glycans at this site. 192 
 193 
Glycan profile analysis of four GMP-grade gp120 proteins 194 
The four GMP-grade gp120 proteins have been produced in stably expressing CHO cell 195 
lines at 50L scale and purified using a multi-step chromatography.  Two separate lots 196 
have been manufactured using the same master cell bank CHO cells and the same 197 
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fermentation and downstream purification process, which allowed us to investigate the 198 
lot-to-lot variability of GMP grade gp120 protein preparations.  The glycan forms 199 
identified from GMP grade gp120 proteins are shown in Fig.4, and the relative amounts 200 
of these glycan forms between two GMP lots are show in Fig.5.  For most gp120 201 
proteins, oligomannose (Man5-Man9) constituted 40-50% of the total glycans, while 202 
complex glycans were about 35-45%, and the rest were hybrid glycans or 203 
paucimannose (Man3-Man4).  The least-processed Man9 and Man8 forms predominated 204 
on clade A and clade B gp120 proteins, while clade C and clade AE proteins showed 205 
higher percentages of Man5.  Percentage of paucimannose showed the largest variation 206 
both between the clades and especially between the two lots of clade C gp120 protein, 207 
where in one of the lots paucimannose represented 23% of all glycans.  Other proteins 208 
showed a more consistent glycan composition for two independent lots.  Complex 209 
glycans were predominantly (63-87%) sialylated and >85% were core fucosylated 210 
(Fig.6).   211 
 212 
Thus all variants of GMP-grade gp120 proteins exhibited high proportion of 213 
oligomannose glycans.  The comparison of the two GMP lots showed mostly 214 
comparable glycan composition for three tested variants of gp120 proteins (clades A, B 215 
and AE) and some variation in the amount of paucimannose for clade C variant. 216 
 217 
PNGSs occupancy analysis of GMP-grade gp120 proteins 218 
Next, PNGS occupancy was mapped for proteins from one of the GMP lots and 219 
compared to the CHO-produced research-grade proteins. The overall occupancy profile 220 
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of the GMP-grade gp120 proteins was generally similar to that of research-grade 221 
proteins, although the GMP proteins tended to have higher proportion of complex 222 
glycans (Fig.7).  Analysis of the protein from the second lot did not reveal any major 223 
differences with the first lot (data not shown). 224 
 225 
The oligomannose glycans were not equally distributed among the PNGSs. N262, 226 
N289/N295, N332, and N363 were enriched in oligomannose, corresponding to the 227 
intrinsic mannose patch that has been noted for HIV Env previously. While present on 228 
all four proteins, the patch was more pronounced for clade A, B, and C proteins, while 229 
oligomannose was more evenly distributed on clade AE protein. Clade C had an 230 
unusual enrichment in oligomannose at the C-terminus (N406, N442, N448, N463) that 231 
was absent in the other three proteins. 232 
 233 
Antigenicity analysis among 4 gp120 proteins 234 
Finally, we sought to test whether any observed lot-to-lot variation in PNGS occupancy 235 
and glycan composition, no matter how minor they may be, had an effect on key 236 
antigenic features of these proteins.  Using the affinity-measuring Octet Qke system and 237 
a panel of probing reagents we tested the preservation of key epitopes on these four 238 
gp120 protein: CD4 binding site (IgG-CD4 and mAb VRC01), V2 loop (mAb 2158), V3 239 
region (mAb R16), gp120 bridging sheet and loop F overlapping with CD4bs (mAb 240 
R53), and glycan forms (mAb 2G12 and mAb PGT128).  The epitope for the 2G12 241 
antibody is believed to include mannose-rich glycans at positions 295, 332, 392, 386, 242 
and 448 (17).  The PGT128 epitopes includes glycans at positions 332 and 301, as well 243 
as the C-terminal end of the V3 loop (18).  While we observed differences in affinities of 244 
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these reagents, the differences between two lots of each clade were minimal (Table 1).  245 
This includes similar affinity of glycan-dependent 2G12 and PGT128 to the lot 2 of clade 246 
C protein, which exhibited the unusually high proportion of paucimannose compared to 247 
lot 1.  Thus, our results demonstrate that observed differences in glycan profiles did not 248 
result in changes in affinity of antibodies targeting key epitopes of four gp120 proteins, 249 
including glycan-binding antibodies, indicating that proteins produced under different 250 
conditions mostly preserved their antigenic structure. 251 
  252 
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Discussion 253 
This report presents the first extensive comparison of glycosylation patterns of 254 
recombinant gp120 proteins from four clades of HIV-1 across two different cell lines, 255 
grown either at laboratory scale or at 50L GMP conditions, purified using different 256 
methods, and across two GMP lots under identical conditions.  Our results show that in 257 
all four gp120 proteins included in the current study, the majority of PNG sites were 258 
occupied by glycans with occupancy rates usually above 50%.  We also found that 259 
among glycans found on these proteins, oligomannose forms represented 40-50% and 260 
were concentrated in the previously described intrinsic mannose patch.  At the same 261 
time, glycosylation profiles were basically very similar, with a low level of variability 262 
under different conditions.  These differences did not affect binding by a panel of 263 
antibodies targeting key immunologic epitopes of gp120 proteins, indicating that the 264 
observed low level glycan differences should not have a major impact on protein 265 
immunogenicity.   266 
 267 
The most prominent feature of HIV Env glycans distinguishing them from glycans on 268 
host proteins is the presence of oligomannose.  In agreement with previous reports, we 269 
observed high proportion of oligomannose glycans (Man5-Man9) on all four proteins 270 
produced under all conditions confirming that this is a characteristic feature of HIV 271 
envelope.  Even though previous studies reported a rather wide range of the percentage 272 
of oligommannose, we consistently observed that in all cases it constituted 40-50% of 273 
glycans.  At least one recent study reported that gp120 derived from infectious virions 274 
contained 50% oligomannose glycans (19), which suggests that glycosylation patterns 275 
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of native Env are generally preserved on the recombinant gp120 proteins.  This 276 
preservation is important for HIV vaccine development aiming to elicit antibodies that 277 
bind and neutralize HIV virions.   278 
 279 
The research-grade gp120 protein was produced in 293F and CHO cells and purified 280 
using lectin columns, while the GMP-grade protein was produced in CHO cells grown at 281 
50L scale and purified using ion exchange columns.  Nevertheless, we found only minor 282 
differences in glycan occupancy and glycan content between proteins produced under 283 
different conditions, indicating that these features are primarily determined by viral 284 
sequence and not by the producing cells or purification process.  285 
 286 
Our comparison of two independent GMP-grade lots of gp120 proteins showed a 287 
consistent glycosylation pattern between them, but also did show some differences, 288 
including a significant increase in paucimannose content in one of the lots of clade C 289 
protein.  It should be noted that this particular lot differed from all other GMP lots in 290 
having a significantly higher yield of the protein.  We do not have enough data to 291 
establish the causal relationship between these two observations, but hypothesize that 292 
high levels of protein production overwhelmed medial and trans-Golgi glycan-293 
processing machinery in producing cells, resulting in secretion of proteins with glycans 294 
that were fully trimmed by cis-Golgi mannosidases but incompletely branched, 295 
extended, and capped.  Further work is needed to test the factors impacting variability 296 
of glycosylation during GMP manufacturing and acceptable variability levels should be 297 
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established.  Special attention should be paid to optimizations that boost protein 298 
production in cells as that may have an impact on cellular glycosylation machinery.   299 
  300 
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Materials and Methods 301 
Production of Non-GMP gp120 proteins 302 
The four gp120 glycoproteins used in this report are from HIV-1 clade A isolate 303 
92UG037.8, clade B isolate JRFL, clade C isolate 93MW965.26 and clade AE 304 
consensus, respectively (16).  The non-GMP research grade HIV-1 gp120 proteins were 305 
produced using two protein expression systems: transiently transfected 293F cell 306 
expression and stably transfected CHO cell expression system.  The codon optimized 307 
gp120-coding DNA inserts cloned in the vector pJW4303 were used in both 293F and 308 
CHO cells.  To produce gp120 proteins from transiently transfect 293F cells, the serum-309 
free 293F cell supernatant was collected at 72 hours after transfection.  To express 310 
gp120 proteins from CHO cells, the serum-free culture supernatant of stable transfected 311 
CHO cells were collected.  The harvested gp120 proteins from both 293F and CHO 312 
cells in research grade were purified using a Lectin column and verified by SDS-PAGE 313 
and Western blot analysis as previously described (20–22).   314 
 315 
Production of GMP grade gp120 proteins 316 
The codon optimized gp120 gene inserts from the same four clades (A, B, C and AE) as 317 
described above for research grade proteins were transfected into CHO DG44 cells 318 
(Invitrogen, CA), respectively, and used to establish the master cell banks.  Each of 319 
these four gp120 expressing stable CHO GD44 cells were grown in 50L bioreactors and 320 
the cell culture supernatants were collected after 8-10 days of fermentation and purified 321 
through a down stream purification process including the anion-exchange, cation-322 
exchange and size-exclusion steps under the GMP conditions.  The purity of each 323 
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gp120 proteins is at the range of 96-98% based on their release certificates.  The same 324 
purified gp120 proteins are currently being tested in a Phase I clinical trial under 325 
HVTN124 protocol at six major US medical centers.   326 
 327 
Detection of occupancy of N-linked glycosylation sites on gp120 proteins  328 
An aliquot of each gp120 protein was buffered to alkaline pH, reduced, alkylated, and 329 
digested with a combination of proteases including Lys-C (Promega), Arg-C (Promega), 330 
Glu-C (Promega), and trypsin (Promega). Following digestion, the proteins were 331 
deglycosylated by Endo-H (Promega) followed by PNGaseF (Glyko®, Prozyme) 332 
treatment in the presence of 18O-water. The resulting peptides were separated on an 333 
Acclaim PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-334 
electrospray ion source of an Orbitrap Fusion™ Lumos™ Tribrid™ mass spectrometer 335 
(Thermo Fisher Scientific) with a 240-min linear gradient consisting of 0.8-80% 336 
acetonitrile over 180 min at a flow rate of 200 nL/min.  Full MS analysis was conducted 337 
in the Orbitrap and automated MS/MS analysis using collision-induced dissociation was 338 
conducted in the ion trap.  Resulting data was analyzed using a combination of 339 
Proteome Discover/Sequest and ProteoIQ/Provalt to generate a 1% false discovery rate 340 
for protein assignments. Site occupancy was calculated using spectral counts assigned 341 
to the 18O-Asp-containing (PNGaseF-cleaved) and/or HexNAc-modified (EndoH-342 
cleaved) peptides and their unmodified counterparts. The positivity cut-off for spectral 343 
counts was set at 10% of the spectral count for the most abundant peptide in each 344 
LC/MS run.  Peptides with spectral counts below the positivity cut-off were not included 345 
in the analysis. 346 
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 347 
N-linked glycan profiling analysis for gp120 proteins  348 
A 20 g aliquot of each gp120 sample was denatured by boiling in SDS.  Upon cooling, 349 
the SDS was removed by precipitation as its potassium salt.  Denatured proteins were 350 
buffered, recombinant peptide-N-glycanase F (PNGaseF) was added, and the mixture 351 
was incubated overnight to release N-linked glycans.  The released N-linked glycans 352 
were freed from residual enzyme, deglycosylated protein, and other contaminants by 353 
passage over C18 Sep-pak.  The released, purified glycans were permethylated using 354 
methyliodide (CH3I) under basic conditions in an aprotic solvent (DMSO), followed by 355 
recovery through organic extraction.  For mass spectrometric analysis, one-half of the 356 
total permethylated glycans released from 20 g of protein (10 g equivalent of protein) 357 
was supplemented by the addition of 10 pmol of an exogenous glycan standard 358 
(maltotetraose) that had previously been permethylated with isotopically heavy 359 
methyliodide (13CH3I).  The sample glycans spiked with standard were directly infused 360 
into an LTQ/Orbitrap mass spectrometer fitted with a nanospray ionization interface 361 
(NSI-MSn; Orbitrap Discovery, Thermo-Fisher).  Glycans were detected in full MS mode 362 
and by total ion mapping (TIM), in which automated CID is performed on small, 363 
overlapping m/z windows.  TIM allows the unbiased detection of ions that give 364 
fragmentation patterns consistent with glycan structural topologies (23).  Glycan signal 365 
intensities were recovered from extracted full MS spectra (Xtract, Thermo-Fisher) and 366 
glycan identities were assigned based on exact mass and CID fragmentation.  367 
Graphical representations of monosaccharide residues are presented in accordance 368 
with the broadly accepted Symbolic Nomenclature For Glycans, SNFG, and glycan 369 
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analysis was performed in keeping with the MIRAGE guidelines for glycomic studies 370 
(24, 25). 371 
 372 
IgG-CD4 protein and gp120-specific monoclonal antibodies (mAbs) 373 
The IgG-CD4 protein used in the Octet Qke assays was a fusion protein of human CD4 374 
domains 1 and 2 with human IgG1 Fc at the C-terminus produced by transient 375 
transfection of 293F cells and His-tagged purification.  The gp120 CD4 binding site 376 
(CD4bs) monoclonal antibody VRC01 (26) was produced from transiently transfected 377 
293F cells using the molecular clones coding for VRC01 heavy and light chains 378 
obtained from NIH AIDS Reagent Program and purified with a Protein A column.  The 379 
gp120 glycan-specific human mAb 2G12 (27) was purchased from Polymun.  The 380 
gp120 glycan specific mAb PGT128 (18) was provided by Wayne Koff from International 381 
AIDS Vaccine Initiative (IAVI).  The gp120-V2 specific human mAb 2158 (28) was 382 
purchased from Dr. Susan Zolla-Pazner’s lab at Mount Sinai School of Medicine.  The 383 
gp120 V3 and C4 specific rabbit mAbs R16 and R53 as reported (29, 30) were 384 
produced from transiently transfected 293F cells using paired heavy and light chain 385 
molecular clones and purified using a Protein A column.  The IgG-CD4 protein and 386 
monoclonal antibodies produced by this study were verified before use.   387 
  388 
Antigenicity analysis of gp120 proteins with Octet Qke   389 
The antigenicity of gp120 proteins was tested using IgG-CD4 and gp120-specific 390 
monoclonal antibodies by Octet Qke (ForteBio) based on biolayer interferometry.  The 391 
IgG-CD4 or each gp120-specific human mAb was individually loaded on to Protein G 392 
sensors at 20 µg/mL and the individual gp120-specific rabbit mAb was loaded to Protein 393 
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A sensors at 10 µg/mL diluted in ForteBio kinetics buffer.  After capture, tips were 394 
washed in kinetics buffer and a baseline measurement recorded.  The tips were then 395 
incubated in wells containing serial dilutions of individual gp120 protein (600nM-0.4nM) 396 
to measure the association rate (Kon) and dissociation rate (Koff).  The antibody binding 397 
kinetics and KD values (Koff/Kon) were collected by the ForteBio Data Analysis 398 
software package v7.1 using a 1:1 fitting model for IgG-CD4 and mAbs VRC01, 399 
PGT128, 2G12, 2158 and R16, and using a 2:1 fitting model for mAb R53. 400 
 401 
 402 
  403 
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 545 
Figure legends 546 
 547 
Figure 1. A. Sequences of the gp120 proteins belonging to clade A (92UG037.8), B 548 
(JRFL), C (93MW965.26), and AE (consensus) aligned to the reference strain HXB2. 549 
Identical amino acids are shown as dots, gaps are indicated with dashes, numbers 550 
correspond to the HXB2 sequence. Variable regions V1-V5 of gp120 are indicated 551 
above the sequences. PNGSs predicted based on the consensus glycosylation 552 
sequence are shown in red font and marked with stars above the sequences. B. 553 
Summary of glycosylation site distribution among the four gp120 proteins. N indicates 554 
the presence of the PNGS in the sequence. 555 
 556 
Figure 2. A. Representative MS spectra of glycans identified on research grade gp120 557 
proteins produced in CHO cells (top) and 293F cells (bottom); The gp120 protein from 558 
clade B (strain JR-FL) protein is shown here as a representative example. Glycan forms 559 
corresponding to the most abundant peaks are shown using the standard glycan icons. 560 
Mass peaks corresponding to oligomannose and complex glycan forms are indicated.  561 
B. Quantitative comparison of relative proportions of various glycan forms (in %) on 562 
CHO- and 293F-derived gp120-B proteins. Glycan structures found at proportions 563 
greater than 10% of total glycans are highlighted in grey. 564 
 565 
Figure 3. A. PNGS occupancy analysis of gp120 proteins expressed in 293F cells (top 566 
row) and CHO cells (bottom row). The percent of glycan occupancy at each PNGS are 567 
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shown for each of the gp120 proteins (clades A, B, C and AE) as indicated on the top of 568 
each panel.  Green and purple bars indicate the percent of oligomannose glycans and 569 
complex glycans, respectively, and grey bars means the site was not occupied by a 570 
glycan. ND indicates peptides not detected.      B. Differences (%) in glycan occupancy 571 
between the 293F- and CHO-produced proteins at each PNGS for each of the gp120 572 
proteins. Percentages for oligomannose and complex glycans were compared at each 573 
site and the difference was plotted based on which protein had larger amount of that 574 
glycan. For example, at position N187 in clade A protein, 293F-derived protein had 25 575 
percentage points more complex glycans than CHO-derived protein, while CHO-derived 576 
protein had 18 percentage points more oligomannose glycans than 293F-derived 577 
protein. 578 
 579 
Figure 4. MS spectra of glycans released from four gp120 proteins (A, B, C and AE) 580 
produced under GMP conditions. Glycan forms corresponding to the most abundant 581 
peaks are shown using the standard glycan icons. Spectra corresponding to 582 
oligomannose and complex glycan forms are highlighted below. 583 
 584 
Figure 5. Quantitation of the types of glycan forms released from two independent lots 585 
(Lot 1 & Lot 2) of gp120 proteins (A, B, C and AE) produced under GMP conditions. 586 
Numbers indicate the percentages of the corresponding glycan forms or structural 587 
classes as color coded for Man5 (M5), Man6 (M6), Man7 (M7), Man8 (M8), Man9 (M9), 588 
Pauci (Man 3 and Man4), Hybrid, and Complex. 589 
 590 
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Figure 6. The analysis of sialylation (left panel) and core fucosylation (right panel) 591 
modifications of complex glycans of each gp120 protein (A, B, C or AE) produced from 592 
2 different GMP lots.  Only complex glycans were included in the analysis.  “1” and “2” 593 
under each bar of the graph indicate lot 1 and lot 2 GMP-grade gp120 proteins, 594 
respectively. “A”, “B”, “C” and “AE” at the bottom of the graph indicate gp120 protein 595 
from clades A, B, C and AE, respectively.  596 
 597 
Figure 7. A. PNGS occupancy analysis of GMP-grade gp120 proteins.  598 
The percent of glycan occupancy at each PNGS is shown for each of the gp120 599 
proteins (clades A, B, C and AE) as indicated on the top of each panel.  Green and 600 
purple bars indicate the oligomannose glycans and complex glycans, respectively, and 601 
grey bars means the site was not occupied by a glycan. ND indicates peptides not 602 
detected.  B. Differences (%) in glycan occupancy in gp120 proteins produced in CHO 603 
cells under research-grade conditions and under GMP conditions at each PNGS. The 604 
plots were generated as described in Figure 3B. 605 
 606 
 607 
  608 
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Table 1.  Binding affinity of two GMP lots of gp120 proteins, Kd (M) 609 
GMP gp120 
proteins 
gp120 specific mAb 
IgG-CD4 CD4bs Glycan V2 V3 C4 
VRC01  2G12  PGT128 2158 R16 R53 
Clade A Lot 1 6.04E-09 3.11E-10 7.68E-10 6.85E-09 5.59E-10 6.76E-08 5.48E-09 
Clade A Lot 2 5.96E-09 1.80E-10 7.62E-10 6.46E-09 2.81E-10 2.76E-08 3.62E-09 
Clade B Lot 1 3.11E-08 <1.0E-12 2.46E-09 4.55E-09 3.49E-10 1.16E-08 7.44E-09 
Clade B Lot 2 2.83E-08 <1.0E-12 2.10E-09 3.26E-09 4.56E-10 1.32E-08 4.87E-09 
Clade C Lot 1 4.53E-08 5.54E-09 3.25E-08 2.61E-08 3.80E-10 5.63E-09 1.57E-07 
Clade C Lot 2 5.21E-08 2.24E-09 2.03E-08 3.31E-08 4.27E-10 4.98E-08 1.15E-07 
Clade AE Lot 1 5.25E-08 8.02E-09 3.71E-08 3.05E-08 5.87E-10 8.89E-09 2.46E-08 
Clade AE Lot 2 3.53E-08 8.62E-09 2.62E-08 3.32E-08 3.22E-10 5.63E-09 1.84E-08 
 610 
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